Erdafitinib, pemigatinib and futibatinib raise blood phosphate in most people, usually in the first weeks. Phosphate is checked with blood tests. A rise is treated with a low-phosphate diet, tablets taken with food that bind phosphate, and sometimes a pause or a lower dose. Report cramps, tingling round the mouth or painful skin lumps. Your own team's plan comes first.
FGFR1 signalling in the proximal tubule, driven by FGF23, limits phosphate reabsorption; blocking it raises serum phosphate. It is an expected pharmacodynamic effect: the US labels report raised phosphate in 73% of patients on erdafitinib (median onset 16 days), 93% on pemigatinib (8 days) and 88% on futibatinib (5 days), with phosphate binders used in 24% and 77% on erdafitinib and futibatinib and phosphate-lowering therapy in 33% on pemigatinib. Prolonged hyperphosphataemia can cause soft tissue mineralisation, cutaneous calcinosis, non-uraemic calciphylaxis and vascular calcification.
The three labels set different thresholds. Diet: erdafitinib restricts phosphate to 600 to 800 mg a day in everyone (US) or from 5.5 mg/dL, 1.75 mmol/L (EU); pemigatinib starts a low-phosphate diet above 5.5 mg/dL; futibatinib starts diet and a binder at 5.5 mg/dL or more. Binder: erdafitinib from 7 mg/dL (2.25 mmol/L) and pemigatinib above 7 mg/dL (both labels say phosphate-lowering therapy or a binder is started in their dose tables, and "consider" or "should be considered" in the erdafitinib warnings and the EU pemigatinib text). Dose: erdafitinib continues at 7 to 8.99 mg/dL, is withheld at 9 to 10 mg/dL (2.91 to 3.20 mmol/L) and restarted at the same dose, may be restarted one level lower after a value above 10 mg/dL, and is stopped for good if 10 mg/dL or more lasts over 2 weeks. Pemigatinib is continued while phosphate-lowering therapy is started, and withheld if phosphate is not under 7 mg/dL within 2 weeks of starting it or, when above 10 mg/dL, not 10 mg/dL or less within 1 week. Futibatinib is reduced, not withheld, above 7 mg/dL, and withheld above 10 mg/dL. Erdafitinib is also the only one whose dose is raised (8 to 9 mg) if phosphate is under 9.0 mg/dL at 14 to 21 days.
Choice of binder is opinion: the EU erdafitinib text suggests a non-calcium binder such as sevelamer; an unfunded review (Kommalapati 2021) prefers lanthanum or calcium-based binders when there is diarrhoea and says acetazolamide can be considered after the binder dose has been raised; an Incyte-sponsored review (Subbiah 2023) says calcium carbonate may be used unless calcium is raised, when sevelamer is preferred. All three EU texts warn of hypophosphataemia: the futibatinib text says binders and diet should be discontinued if treatment stops or phosphate falls below normal, the pemigatinib text says this should be considered during treatment breaks or if phosphate falls below normal, and the erdafitinib text says to discontinue them if phosphate falls below normal. No independent guideline was found.
Why: A starting value is needed to judge later rises, and the dose rules are written around phosphate levels.
“Phosphate concentrations should be assessed prior to the first dose and then monitored monthly.”
Why: The review says phosphate is in almost all food, with more in processed and animal foods, dairy, whole grains, lentils and nuts, so cutting it down needs specific swaps.
“Patients on FGFR inhibitors should invariably be educated about dietary modifications, to reduce the risk of developing hyperphosphatemia”
Why: The labels report that phosphate first rose after a median of 5 days (futibatinib), 8 days (pemigatinib) and 16 days (erdafitinib). The pemigatinib and futibatinib labels set no schedule before it is raised.
“Monitor for hyperphosphatemia throughout treatment.”
Why: The label calls the rise in phosphate a pharmacodynamic effect of the drug and sets the dose by this one reading. The EU text words the second condition as no drug-related toxicity, and says phosphate should not guide a dose increase after day 21.
“Increase the dose of BALVERSA to 9 mg once daily if serum phosphate level is < 9.0 mg/dL and there are no ocular disorders or Grade 2 or greater adverse reactions.”
Janssen, via DailyMed (US National Library of Medicine) 2025
Why: They can alter the phosphate reading used to set the dose, and the EU text says vitamin D may add to raised phosphate and calcium.
“Supplementation with vitamin D in patients receiving erdafitinib is not recommended due to potential contribution to increased serum phosphate and calcium levels.”
Why: Each label puts diet before, or alongside, phosphate-lowering medicine. The futibatinib label starts diet at 5.5 mg/dL or more.
“Monitor for hyperphosphatemia and initiate a low phosphate diet when serum phosphate level is > 5.5 mg/dL.”
Why: A binder reduces the phosphate absorbed from food. The erdafitinib dose table says to start one at 7 to 8.99 mg/dL, while its warnings section, quoted here, says to consider one above 7.0 mg/dL; the EU pemigatinib text also says "should be considered". The pemigatinib and futibatinib labels then check phosphate weekly.
“If serum phosphate is above 7.0 mg/dL, consider adding an oral phosphate binder until serum phosphate level returns to <7.0 mg/dL.”
Janssen, via DailyMed (US National Library of Medicine) 2025
Why: The review prefers lanthanum to calcium-based binders when calcium is already high, and says sevelamer, magnesium-based binders and sucroferric oxyhydroxide can worsen the diarrhoea these medicines cause. Sources differ on which to use first (see variants).
“Similarly, lanthanum is preferred over calcium-based regimens in patients with baseline hypercalcemia and who are at high risk of vascular calcifications.”
Why: The review says side effects and frequent dosing make binders hard to keep taking, and that low phosphate in the trials may have come from over-correction with binders. A second review gives the same advice to limit hypophosphataemia.
“Hence, phosphate binders should be administered at the lowest possible dose and dose escalation should be considered based on the response and desired phosphorous levels.”
Why: Each medicine has its own rule, and they are not interchangeable (see variants).
“Withhold BALVERSA with weekly reassessments until level returns to <7 mg/dL. Then restart BALVERSA at the same dose level.”
Janssen, via DailyMed (US National Library of Medicine) 2025
Why: The labels say raised phosphate can lead to mineral deposits in soft tissue, skin and blood vessels. The quoted rule is futibatinib's; the three rules are set out under variants.
“Withhold LYTGOBI until phosphate is ≤7 mg/dL and resume LYTGOBI at the next lower dose.”
Why: The labels name cramps, numbness and tingling as symptoms of an acute change in phosphate, and list skin calcinosis and non-uraemic calciphylaxis among the effects of raised phosphate. The US pemigatinib and futibatinib labels name the cramps, numbness and tingling but not skin lesions.
“Advise patients to immediately inform their healthcare provider of painful skin lesions or any symptoms related to acute change in phosphate levels such as muscle cramps, numbness, or tingling around the mouth”
Janssen, via DailyMed (US National Library of Medicine) 2025
Why: The EU texts warn of low phosphate, which when severe may present with confusion, seizures and muscle weakness. Only the pemigatinib text words this as something to consider.
“Discontinuing phosphate-lowering therapy and diet should be considered during Pemazyre treatment breaks or if serum phosphate level falls below normal range.”
Why: The same medicines can cause retinal pigment epithelial detachment, which may blur vision; it is managed separately from phosphate. The intervals differ by medicine and between the US and EU texts.
“Perform a comprehensive ophthalmological examination including OCT prior to initiation of PEMAZYRE and every 2 months for the first 6 months and every 3 months thereafter during treatment.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
There is no independent guideline; the regulators' texts are the firmest source, and they differ by medicine and, for erdafitinib, between the US and the EU. All agree on monitoring phosphate, a low-phosphate diet, phosphate-lowering therapy once phosphate is above 7 mg/dL (2.25 mmol/L) at the latest, restarting at a lower dose after the medicine has been withheld for a value above 10 mg/dL (3.20 mmol/L), and telling patients to report cramps, numbness and tingling round the mouth immediately (the erdafitinib texts and the EU futibatinib leaflet add painful skin lesions). They differ on when diet starts (everyone on erdafitinib in the US; from 5.5 mg/dL in the EU and for pemigatinib), when a binder starts (5.5 mg/dL for futibatinib, 7 mg/dL for the others), what happens between 7 and 10 mg/dL (erdafitinib continues to 8.99 and is withheld from 9; pemigatinib continues for up to 2 weeks on phosphate-lowering therapy and is withheld if phosphate is not under 7 mg/dL by then; futibatinib is reduced by one dose level), and what happens above 10 mg/dL (erdafitinib and futibatinib are withheld; pemigatinib is withheld only if phosphate is not 10 mg/dL or less within 1 week). Weekly checks are written into the pemigatinib and futibatinib rules once therapy starts, and into the erdafitinib rule while the drug is withheld. On the choice of binder the sources disagree and none is graded: the EU erdafitinib text suggests a non-calcium binder such as sevelamer carbonate; an unfunded review prefers lanthanum or calcium-based binders in people with diarrhoea and lanthanum when calcium is high; an Incyte-sponsored review says calcium carbonate may be used unless calcium is raised, when sevelamer is preferred. All three EU texts add that binders and diet should be discontinued if phosphate falls below normal (the pemigatinib text says this should be considered); the futibatinib text says the same when treatment is stopped and the pemigatinib text during treatment breaks.
Janssen, via DailyMed (US National Library of Medicine) 2025 · Incyte, via DailyMed (US National Library of Medicine) 2026 · Taiho, via DailyMed (US National Library of Medicine) 2026 · European Medicines Agency 2026 · European Medicines Agency 2026 · European Medicines Agency 2026 · Cancers (Kommalapati et al.); no external funding 2021 · Cell Reports Medicine (Subbiah and Verstovsek); sponsored by Incyte Corporation 2023
Where it differs: Phosphate at 14 to 21 days decides whether the dose rises from 8 mg to 9 mg (only if under 9.0 mg/dL), then monthly checks. Under 7 mg/dL: continue. 7 to 8.99 mg/dL (2.25 to 2.90 mmol/L): continue, start a binder, and reduce the dose if it stays at 7 mg/dL or more for 2 months. 9 to 10 mg/dL (2.91 to 3.20 mmol/L): withhold with weekly checks until under 7 mg/dL, restart at the same dose, and reduce if it stays at 9 mg/dL or more for 1 month. Above 10 mg/dL: withhold with weekly checks until under 7 mg/dL, then restart at the first reduced dose (the US text says "may restart"), and stop for good if 10 mg/dL or more lasts over 2 weeks. The US text restricts phosphate to 600 to 800 mg a day in all patients; the EU text does so from 5.5 mg/dL (1.75 mmol/L), says a non-calcium binder such as sevelamer carbonate should be considered for persistent rises, advises against vitamin D supplements, and stops the drug for good for a significant change in kidney function or grade 3 hypocalcaemia due to hyperphosphataemia.
Evidence: Regulatory texts. Raised phosphate in 73% of 479 patients (US pooled safety population), median onset 16 days; 24% took binders; vascular calcification in 0.2%. The EU text reports hyperphosphataemia as an adverse event in 78.5% and hypophosphataemia in 5.6%.
Janssen, via DailyMed (US National Library of Medicine) 2025 · European Medicines Agency 2026
Where it differs: Low-phosphate diet above 5.5 mg/dL. Above 7 and up to 10 mg/dL: start phosphate-lowering therapy and check weekly; withhold if not under 7 mg/dL within 2 weeks of starting it; restart at the same dose the first time and a lower dose for later recurrences. Above 10 mg/dL: phosphate-lowering therapy and weekly checks; withhold if not 10 mg/dL or less within 1 week; restart at the next lower dose when under 7 mg/dL; stop for good if it recurs above 10 mg/dL after 2 dose reductions.
Evidence: US prescribing information: hyperphosphataemia by laboratory value in 93% of 635 patients, median onset 8 days, phosphate-lowering therapy in 33%. The EU text gives the same thresholds, says in its posology text that adding phosphate-lowering therapy above 7 mg/dL "should be considered", and adds closer follow-up of bone mineralisation in people with high or low phosphate.
Incyte, via DailyMed (US National Library of Medicine) 2026 · European Medicines Agency 2026
Where it differs: Diet and phosphate-lowering therapy from 5.5 mg/dL, with weekly checks. Above 7 and up to 10 mg/dL: reduce to the next lower dose rather than withhold; reduce again if not 7 mg/dL or less within 2 weeks; withhold only if still not controlled 2 weeks after the second reduction. Above 10 mg/dL: withhold until 7 mg/dL or less and restart at the next lower dose; stop for good if not 7 mg/dL or less within 2 weeks after 2 interruptions and reductions.
Evidence: US prescribing information: hyperphosphataemia in 88% of 318 patients, median onset 5 days, binders in 77%. In the manufacturer's pooled analysis of 469 patients (supported by Taiho Oncology) hyperphosphataemia occurred in 82.1%, was grade 3 or higher in 18.8% by the trial's own phosphate-based grading, and was the commonest reason for dose modification (23.5%).
Taiho, via DailyMed (US National Library of Medicine) 2026 · European Medicines Agency 2026 · Clinical Cancer Research (Meric-Bernstam et al.); supported by Taiho Oncology 2024
Where it differs: Non-calcium binder such as sevelamer carbonate (EU erdafitinib text); lanthanum or calcium-based binders rather than sevelamer, magnesium-based binders or sucroferric oxyhydroxide when the person has diarrhoea, and lanthanum rather than calcium when calcium is high or vascular calcification is a risk (Kommalapati 2021); calcium carbonate "may be used" when calcium is normal and sevelamer is preferred when it is raised (Subbiah 2023).
Evidence: Opinion in each case; Kommalapati 2021 says most of the data on binders come from kidney medicine, and none of the three sources cites a trial comparing binders in people on FGFR inhibitors. Kommalapati 2021 had no external funding; Subbiah 2023 was sponsored by Incyte.
European Medicines Agency 2026 · Cancers (Kommalapati et al.); no external funding 2021 · Cell Reports Medicine (Subbiah and Verstovsek); sponsored by Incyte Corporation 2023
Where it differs: Acetazolamide, which the review classes as a phosphaturic agent (one that increases phosphate elimination), can be considered after the binder dose has been raised. The review's table gives a starting dose of 250 mg once a day and a maximum of 250 mg two or three times a day, and pairs it with the maximum binder dose at 7 mg/dL or more. The review says it is contraindicated in advanced liver dysfunction and should be avoided with extensive liver metastases or extensive intrahepatic cholangiocarcinoma with compromised liver function.
Evidence: Opinion in the Kommalapati review. Subbiah 2023 says only that it "may also be used"; in the Meric-Bernstam pooled analysis 26.4% of patients on futibatinib 20 mg took it. None of the six regulatory texts mentions it, and the papers read report no trial of it in this setting.
Cancers (Kommalapati et al.); no external funding 2021 · Cell Reports Medicine (Subbiah and Verstovsek); sponsored by Incyte Corporation 2023 · Clinical Cancer Research (Meric-Bernstam et al.); supported by Taiho Oncology 2024
Where it differs: Dietary advice once phosphate rises more than 25% above baseline in the first week; a binder considered at 5.5 to 6.9 mg/dL for any FGFR inhibitor; dose reduction considered once phosphate is 7 mg/dL or more on two occasions, or 10 mg/dL or more once, despite diet and binders.
Evidence: Kommalapati 2021, an unfunded narrative review, which says there is no optimal cut-off for dose reduction. It predates the futibatinib label and differs from all three labels.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Phosphate restricted to 600 to 800 mg a day and phosphate-raising agents avoided (erdafitinib, US) “Restrict dietary phosphate intake (600–800 mg daily) and avoid concomitant use of agents that may increase serum phosphate levels.” | Regulatory label; not graded | Janssen, via DailyMed (US National Library of Medicine) 2025 |
| Erdafitinib stopped for good if phosphate of 10 mg/dL or more lasts over 2 weeks “If hyperphosphatemia (≥10 mg/dL) for >2 weeks, discontinue BALVERSA permanently.” | Regulatory label; not graded | Janssen, via DailyMed (US National Library of Medicine) 2025 |
| A non-calcium binder for persistently raised phosphate (erdafitinib, EU) “adding a non-calcium containing phosphate binder (e.g., sevelamer carbonate) should be considered as needed” | Regulatory product information; not graded | European Medicines Agency 2026 |
| Pemigatinib withheld if phosphate is not under 7 mg/dL within 2 weeks of a binder “Withhold PEMAZYRE if levels are not < 7 mg/dL within 2 weeks of starting phosphate lowering therapy.” | Regulatory label; not graded | Incyte, via DailyMed (US National Library of Medicine) 2026 |
| Futibatinib: diet and binder from 5.5 mg/dL “Initiate a low phosphate diet and phosphate lowering therapy when serum phosphate level is ≥5.5 mg/dL.” | Regulatory label; not graded | Taiho, via DailyMed (US National Library of Medicine) 2026 |
| Futibatinib: binder from 5.5 mg/dL (EU) “A phosphate-lowering therapy should be initiated when serum phosphate level is ≥ 5.5 mg/dL.” | Regulatory product information; not graded | European Medicines Agency 2026 |
| Stop binders and diet if treatment stops or phosphate falls below normal (futibatinib, EU) “If Lytgobi treatment is stopped or serum phosphate level falls below normal range, phosphate-lowering therapy and diet should be discontinued.” | Regulatory product information; not graded | European Medicines Agency 2026 |
| Closer follow-up of bone mineralisation with high or low phosphate (pemigatinib, EU) “For patients presenting with hyperphosphataemia or hypophosphataemia, additional close monitoring and follow-up is recommended regarding dysregulation of bone mineralization.” | Regulatory product information; not graded | European Medicines Agency 2026 |
| Lanthanum and calcium-based binders preferred in people with diarrhoea “In patients who also have FGFR-inhibitor-associated diarrhea, lanthanum and calcium-based regimens are preferred over magnesium-based regimens, sevelamer, and sucroferric oxyhydroxide as the latter can exacerbate the diarrhea caused by FGFR inhibitors.” | Narrative review, no external funding; not graded | Cancers (Kommalapati et al.); no external funding 2021 |
| Sevelamer when calcium is also raised, calcium carbonate otherwise “If a patient has hypercalcemia and hyperphosphatemia, then sevelamer is preferred. If a patient has only hyperphosphatemia with no elevation in calcium levels, then calcium carbonate may be used.” | Narrative review sponsored by Incyte; not graded | Cell Reports Medicine (Subbiah and Verstovsek); sponsored by Incyte Corporation 2023 |
| Binders started at the lowest possible dose “When initiating phosphate binders, the lowest possible dose should be used to mitigate development of hypophosphatemia.” | Narrative review sponsored by Incyte; not graded | Cell Reports Medicine (Subbiah and Verstovsek); sponsored by Incyte Corporation 2023 |
| No agreed phosphate cut-off for reducing the dose “Though there is no optimal cut off phosphate values to consider a dose reduction of the FGFR inhibitor, dose reduction should be considered once the phosphate levels reach ≥7 mg/dL (on two separate occasions) or one episode of ≥10 mg/dL despite optimization of diet and phosphate binding agents.” | Narrative review, no external funding; not graded | Cancers (Kommalapati et al.); no external funding 2021 |
| Eye examinations monthly for 4 months then every 3 months (erdafitinib) “Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms.” | Regulatory label; not graded | Janssen, via DailyMed (US National Library of Medicine) 2025 |
Shares Futibatinib, Pemigatinib, FGFR2.
Shares Erdafitinib, Futibatinib, FGF / FGFR signalling, Pemigatinib.
Shares Futibatinib, Pemigatinib, FGFR2.
Shares Futibatinib, Pemigatinib, FGFR2.
Shares Erdafitinib, FGFR2.
Shares Futibatinib, FGFR2.
Shares FGFR1, FGF / FGFR signalling.
Shares Erdafitinib, FGFR2.